TABLE 3.
Nine-Year OS, Prostate Cancer-Specific Survival, and Multivariate HRs for Men With Metastatic Prostate Cancer
| Variable | No. | OS |
Prostate Cancer-Specific Survival |
||||
|---|---|---|---|---|---|---|---|
| No. of Events | 9-Year OS, % | No. of Prostate Events | 9-Year Prostate Cancer-Specific Survival, % | Univariate P | Multivariate HR (95% CI) | ||
| Age at diagnosis, y | .24 | ||||||
| <60 | 58 | 41 | 29 ± 6.0 | 36 | 35 ± 6.6 | ||
| 60–69 | 98 | 77 | 17 ± 4.3 | 67 | 20 ± 5.0 | ||
| ≤70 | 158 | 142 | 9 ± 2.4 | 89 | 24 ± 4.7 | ||
| Race | .079 | ||||||
| White | 155 | 126 | 15 ± 3.3 | 89 | 25 ± 4.7 | 1.00 | |
| Nonwhite | 159 | 134 | 15 ± 2.9 | 103 | 25 ± 4.0 | 0.93 (0.55–1.58) | |
| Marital status | <.001 | ||||||
| Married | 172 | 139 | 16 ± 3.0 | 104 | 25 ± 4.1 | 1.00 | |
| Not married | 142 | 121 | 13 ± 3.0 | 88 | 26 ± 4.5 | 1.55 (1.03–2.31) | |
| Insurance | <.001 | ||||||
| Private | 108 | 88 | 15 ± 3.8 | 72 | 20 ± 4.7 | 1.00 | |
| Public | 185 | 160 | 12 ± 2.5 | 111 | 26 ± 4.1 | 1.07 (0.68–1.66) | |
| None/unknown | 21 | 12 | 43 ± 10.8 | 9 | 52 ± 11.6 | 0.41 (0.15–1.12) | |
| Registry region | .014 | ||||||
| 1 | 56 | 40 | 29 ± 6.0 | 31 | 38 ± 7.0 | 1.00 | |
| 2 | 69 | 62 | 10 ± 3.6 | 49 | 18 ± 5.4 | 1.21 (0.72–2.02) | |
| 3 | 18 | 14 | 22 ± 9.8 | 10 | 39 ± 12.2 | 0.75 (0.29–1.92) | |
| 4 | 65 | 60 | 8 ± 3.3 | 44 | 17 ± 6.0 | 1.25 (0.73–2.15) | |
| 5 | 32 | 23 | 28 ± 7.9a | 16 | 42 ± 9.8b | 0.71 (0.30–1.66) | |
| 6 | 41 | 31 | 27 ± 6.9a | 22 | 39 ± 8.6b | 0.88 (0.41–1.89) | |
| 7 | 33 | 30 | 9 ± 5.0 | 20 | 18 ± 8.9 | 1.36 (0.57–3.25) | |
| Urban/rural residence | <.001 | ||||||
| Urban | 160 | 134 | 15 ± 2.9 | 101 | 25 ± 4.0 | 1.00 | |
| Rural | 54 | 44 | 8 ± 4.9 | 28 | 19 ± 10.4 | 0.76 (0.37–1.54) | |
| Mixed | 99 | 82 | 15 ± 3.9 | 63 | 22 ± 5.2 | 1.26 (0.80–1.97) | |
| SES | .001 | ||||||
| Low | 98 | 88 | 10 ± 3.0 | 66 | 21 ± 5.1 | 1.00 | |
| Middle | 73 | 59 | 17 ± 4.7 | 43 | 27 ± 6.3 | 0.77 (0.39–1.51) | |
| High | 142 | 113 | 17 ± 3.5 | 83 | 26 ± 4.8 | 0.79 (0.44–1.40) | |
| Comorbidity severity | <.001 | ||||||
| None | 84 | 67 | 17 ± 4.5 | 54 | 25 ± 5.7 | 1.00 | |
| Mild | 135 | 115 | 13 ± 3.1 | 88 | 21 ± 4.2 | 1.04 (0.65–1.68) | |
| Moderate/severe | 71 | 62 | 11 ± 3.9 | 37 | 29 ± 7.9 | 0.76 (0.42–1.38) | |
| Unknown | 24 | 16 | 31 ± 10.0 | 13 | 39 ± 11.4 | 0.48 (0.17–1.30) | |
| PSA, ng/mL | <.001 | ||||||
| ≤10 | 39 | 28 | 23 ± 7.5 | 20 | 34 ± 9.4 | 1.00 | |
| >10 | 262 | 220 | 14 ± 2.3 | 164 | 24 ± 3.3 | 1.67 (0.95–2.94) | |
| Gleason score | <.001 | ||||||
| 2–6 | 25 | 16 | 33 ± 9.9 | 7 | 58 ± 12.9 | 1.00 | |
| 7 | 75 | 58 | 21 ± 4.9 | 43 | 33 ± 6.4 | 3.05 (1.13–8.24) | |
| 8–10 | 179 | 153 | 12 ± 2.7 | 119 | 19 ± 3.8 | 5.39 (2.13–13.65) | |
| Treatment group | .002 | ||||||
| Conservative | 222 | 185 | 14 ± 2.5 | 134 | 24 ± 3.7 | 0.81 (0.50–1.30) | |
| Aggressive | 92 | 75 | 17 ± 4.1 | 58 | 27 ± 5.3 | 1.00 | |
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; OS, overall survival; PSA, prostate-specific antigen; SES, socioeconomic status.
a
OS at 5 years.
b
Prostate cancer-specific survival at 5 years.